This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
While scientists in pharmaceutical laboratories spearhead the development of hepatitis B virus (HBV) vaccines by technological means, the worldwide search for a safe, effective, and less expensive way to fight the spread of HBV has led, in at least one instance, to "home production" of a protective immunization medium. Its developer says the method is reproducible and can be used on a large scale in any country where conditions similar to those in his native Nigeria prevail.
This Nigerian physician, Abdulsalami Nasidi, MD, and colleagues have developed a simplified five-step method for production of plasma-derived HBV vaccine. Supported by the National Institute for Medical Research of Nigeria in Lagos—where he is director of the newly established hepatitis laboratory—Nasidi began his project because, he says: "Vaccines developed by drug companies are too expensive for us."
In an interview with JAMA MEDICAL NEWS in San Francisco at the recent International Symposium on
One approach to vaccine need—'home production'. JAMA. 1984;251(21):2766–2767. doi:10.1001/jama.1984.03340450004002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: